Home

uniQure N.V. - Ordinary Shares (QURE)

26.06
-4.38 (-14.39%)
NASDAQ · Last Trade: Nov 5th, 6:26 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close30.44
Open27.55
Bid25.61
Ask25.80
Day's Range25.52 - 27.99
52 Week Range5.350 - 71.50
Volume8,926,289
Market Cap1.43B
PE Ratio (TTM)-6.648
EPS (TTM)-3.9
Dividend & YieldN/A (N/A)
1 Month Average Volume4,107,044

Chart

About uniQure N.V. - Ordinary Shares (QURE)

Uniqure is a biotechnology company focusing on the development of gene therapies for the treatment of genetic diseases. The company is dedicated to creating innovative and transformative therapies that target various conditions, particularly those related to genetic disorders and rare diseases. By leveraging advanced gene-editing technologies, Uniqure aims to provide long-lasting solutions that address the underlying causes of these ailments. Their pipeline includes research and development efforts centered on delivering effective treatments to improve patients' lives through the unique potential of gene therapy. Read More

News & Press Releases

Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejectionbenzinga.com
Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade.
Via Benzinga · November 5, 2025
UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V. on Behalf of uniQure Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · November 5, 2025
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm
LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of the securities laws.
By Schall Law · Via GlobeNewswire · November 5, 2025
uniQure Stock Tumbled 56% Today: What’s The FDA Angle?stocktwits.com
Via Stocktwits · November 3, 2025
Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Druginvestors.com
The company was nearing approval for a treatment for a rare, neurodegenerative disease. Then, the FDA spoke.
Via Investor's Business Daily · November 5, 2025
Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 5, 2025
Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · November 5, 2025
uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (QURE)
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · November 4, 2025
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapybenzinga.com
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
Via Benzinga · November 4, 2025
NASDAQ: QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).
Insperity Posts Downbeat Q3 Results, Joins IAC, Archer-Daniels-Midland And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 4, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 4, 2025
Why Upwork Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · November 4, 2025
These stocks are moving in today's after hours sessionchartmill.com
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · November 3, 2025
Which stocks are moving on Monday?chartmill.com
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · November 3, 2025
Gold Edges Higher; ISM Manufacturing PMI Falls In Octoberbenzinga.com
Via Benzinga · November 3, 2025
UniQure Shares Drop After FDA Shifts Stance On Huntington's Gene Therapy Databenzinga.com
UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's disease, delaying BLA plans.
Via Benzinga · November 3, 2025
Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session.chartmill.com
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · November 3, 2025
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · November 3, 2025
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · November 3, 2025
Gapping stocks in Monday's sessionchartmill.com
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · November 3, 2025
uniQure N.V. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QURE
The DJS Law Group announces that it is investigating claims on behalf of investors of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of the securities laws.
By The DJS Law Group · Via Business Wire · November 3, 2025
Nasdaq Surges 1%; ON Semiconductor Posts Upbeat Q3 Earningsbenzinga.com
Via Benzinga · November 3, 2025
Uniqure Plummets 59% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapyinvestors.com
An analyst described the FDA feedback as "confusing" and "unexpected" for the experimental Huntington's disease treatment.
Via Investor's Business Daily · November 3, 2025
Discover the top movers in Monday's pre-market session.chartmill.com
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · November 3, 2025